RxDoctor Payments DataLook up a doctor →

Matthew Caldwell, MD

Family Medicine · Athens, ALNPI 1619236064

Payments from drug & device makers

$4,104,868in general payments, 2019–2025

Across 893 payments — averaging $4596.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$3.5M
  • Bavarian Nordic A/s$298K
  • Janssen Research & Development, LLC$267K
  • Amgen$58K
  • GSK$5K
  • AbbVie$2K
  • plus $6K from 38 others

What the payments were for

  • Food & beverage$8,90299%
  • Education$801%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,104,868 in reported general payments places this provider in the 95th percentile of 1,680 family medicine providers in Alabama.

See all family medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$170,348
Medicare patients
358
Services billed
5,601

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide110$119,870
JardianceEmpagliflozin95$81,002
Trelegy ElliptaFluticasone/Umeclidin/Vilanter93$73,880
EliquisApixaban77$61,331
JanuviaSitagliptin Phosphate73$58,747
MounjaroTirzepatide39$45,678
FarxigaDapagliflozin Propanediol53$22,388
Repatha SureclickEvolocumab19$21,914
LinzessLinaclotide18$12,216
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$11,654
XareltoRivaroxaban18$11,327
TradjentaLinagliptin15$8,739
Tresiba Flextouch U-100Insulin Degludec16$7,579
MyrbetriqMirabegron15$7,512
SymbicortBudesonide/Formoterol Fumarate16$6,168

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$752$119,870110 claims
Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr$348$94,728121 claims
GSKTrelegy Ellipta, Shingrix$5,390$78,720116 claims
PfizerEliquis$3,468,712$61,33177 claims
MerckJanuvia$40$58,74773 claims
Lilly USA, LLCMounjaro$635$45,67839 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$1,038$40,21080 claims
AbbVieLinzess$2,132$12,21618 claims
Johnson & JohnsonXarelto$91$11,32718 claims
Astellas Pharma US IncMyrbetriq$206$7,51215 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,680 family medicine providers in Alabama.

Other family medicine in Athens

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →